ArticleEuropean journal of pediatrics2026
Systemic hypertension in very preterm infants: a population-based study.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study is to assess incidence, temporal trend, risk factors, clinical characteristics, management and outcomes of systemic hypertension (SH) in very preterm infants. We conducted a retrospective population-based study including preterm infants born at < 31 weeks' gestation in Nova Scotia and Prince Edward Island, Canada, between 2002 and 2016. Patients diagnosed with SH requiring treatment before discharge from the NICU, or on 3 consecutive occasions during outpatient follow-up, were compared with matched controls (for gestational age, sex and birth weight). Perinatal data, details of SH, neonatal course and neurodevelopmental outcomes at 18 months corrected gestational age were reviewed. Of the 935 infants who met inclusion criteria, 102 (10.9%) had SH. Mean (SD) gestational age at birth was 27.1 (1.9) weeks. Median (IQR) corrected gestational age at diagnosis was 40 (37, 57) weeks. There was a significant reduction in the incidence of SH over the 15-year study period from 12.8 to 7.2% (p = 0.02). On logistic regression analysis, only intrapartum magnesium sulfate was associated with decreased odds of SH (aOR 0.25, 95% CI 0.08, 0.73). There were no significant differences in mortality, length of hospital stays, mean mental development index, cognitive, language, and motor scores between SH patients and their matched controls.
conclusionThe incidence of SH in very preterm infants was 10.9% with a declining trend over the study period. Administration of antenatal magnesium sulfate was associated with reduced odds of SH. Systemic hypertension does not appear to be negatively associated with neonatal mortality, length of hospital stay, or neurodevelopmental outcomes at 18 months corrected age. WHAT IS KNOWN: • Systemic hypertension in very preterm infants is not uncommon. • This significant health condition warrants more attention and research to guide clinical practice. WHAT IS NEW: • The incidence of systemic hypertension in our study was 10.9% with a declining trend. • Approximately one third of infants were diagnosed after NICU discharge. • Approximately two thirds of the hypertensive infants had nephrocalcinosis. • Systemic hypertension was not associated with increased mortality, short-term morbidities, or neurodevelopmental impairment at 18 months corrected age.
Indexed as
Identifiers
42047815What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.